Exercise Tolerance and Hemodynamic Parameters in PAH and CTEPH 341 P ulmonary hypertension (PH) is a clinical syndrome characterized by progressive obstructive pulmonary vasculopathy, leading to increased pulmonary vascular resistance (PVR), elevated pulmonary artery pressure, and right ventricular failure.
Purpose: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are the main subgroups of pulmonary hypertension (PH). Despite differences in their etiologies, both diseases are characterized by vascular remodeling, resulting in progressive right heart failure. Noninvasive periodic evaluation of exercise tolerance has become increasingly important. Cardiopulmonary exercise testing (CPET) and a 6-minute walk test (6MWT) are now both recommended for evaluating exercise tolerance, but there is insuffi cient knowledge about possible differences in the associations of exercise tolerance with right heart catheterization (RHC) data for patients with PAH and CTEPH. Methods: A retrospective study was performed with 57 patients with PH (24 with PAH and 33 with CTEPH) all of whom underwent echocardiography, CPET, 6MWT, and RHC. Results: For both patients with PAH and CTEPH, peak heart rate during CPET was signifi cantly higher than that from 6MWT, whereas minimum peripheral oxygen saturation during CPET and 6MWT was similar. For patients with PAH, significant correlations were observed between peak V · o 2 and cardiac index (CI) ( r = 0.59; P = .002) and between V · E / V · co 2 slopes and CI ( r = − 0.46, P = .02), as well as a nonsignifi cant correlation tendency for peak V o 2 and pulmonary vascular resistance (PVR) and for V · E / V · co 2 and PVR ( r = − 0.39; P = .05; and r = 0.39; P = .06, respectively). For patients with CTEPH, however, a signifi cant correlation was observed only between V · E / V · co 2 slopes and CI ( r = − 0.38; P = .02). Conclusion: PH etiology should be considered when assessing exercise tolerance, whereas CPET can be effective in addition to hemodynamic assessment by means of RHC for periodic evaluation during followup. coronary artery disease, defi ned as a single coronary artery stenosis of > 50% of the diameter of a major epicardial vessel or a history of myocardial infarction; (3) congenital heart disease; and (4) more than mild aortic and/or mitral valvular heart disease. All patients were in clinically stable condition at the time of enrollment. This study was approved by the local ethics committee of our institution and written informed consent was obtained from all patients.
CPET
CPET was conducted using a cycle ergometer (Strength Ergo 8; Mitsubishi Electric Engineering, Tokyo, Japan), performed in accordance with the American Thoracic Society guidelines and was done within 1 week following RHC. 11 One minute of upright rest was followed by 4 minutes of unloaded pedaling and then progressive increments in the workload (5 or 10 W/min) to symptom-limited maximum tolerance. The rate of increase in the workload was empirically determined by the supervising physical therapist and physician on the basis of the patient's medical history and clinical data. Test duration was between 7 and 14 minutes (from unloaded pedaling to peak exercise) for all patients. Oxygen uptake ( V · o 2 ), carbon dioxide production ( V · co 2 ), and minute ventilation ( V · E ) were measured continuously using breath-by-breath analysis (Cpex-1; Inter-Reha, Tokyo, Japan). Peak V · o 2 was defi ned as the average V · o 2 data collected during the last 30 seconds of peak exercise. 7 Ventilatory effi ciency during exercise was expressed as the slope of V · E versus V · co 2 over the linear component of the plot of V · E versus V · co 2 . 12 Peripheral oxygen saturation (Sp o 2 ) was measured continuously using pulse oximetry with a fi nger probe (Smart Pulse, Fukuda Denshi, Tokyo, Japan).
6MWT
6MWT was performed in accordance with the American Thoracic Society guidelines.
11 6MWT was conducted in a 30-m long, straight corridor under the guidance of a physical therapist or physician. At the end of the test, the 6-minute walk distance (6MWD) was recorded. Sp o 2 was measured continuously with a fi nger probe (Smart Pulse, Fukuda Denshi, Tokyo, Japan). HEMODYNAMIC MEASUREMENTS A Swan-Ganz catheter was used for hemodynamic measurements at rest. mPAP, pulmonary capillary wedge pressure, PVR, and cardiac index (CI) were estimated according to the Fick principle. An investigator blinded to the echocardiographic, CPET, and 6MWT data measured the pressure.
STATISTICAL ANALYSIS
Continuous variables were expressed as mean values ± standard deviation or percentages, whereas categorical data were summarized as frequencies and percentages. All group data were compared by using a 2-tailed Student t test for unpaired data. Univariate linear correlation analysis was used for comparison of RHC and CPET data. For all tests, a P value of < .05 was considered statistically signifi cant. All analyses were performed using MedCalc Software version 12.1 (MedCalc Software, Mariakerke, Belgium).
RESULTS

BASELINE CHARACTERISTICS OF PATIENTS WITH PH
The baseline clinical, echocardiographic, and hemodynamic data of the 57 patients with PH are summarized in Table 1 . Twenty-four patients (42%) were found to have PAH and the remaining 33 (58%) CTEPH. Twenty-four patients (42%) took PH-specifi c drugs at the time of enrollment. Compared with the patients with CTEPH, the patients with PAH were more likely to be younger, and have a higher resting heart rate (HR), lower tricuspid annular plane systolic excursion as measured by echocardiography, and higher prevalence of use of diuretics. CPET and 6MWT were successfully performed for all patients, and the data are summarized in Table 2 . At peak exercise, patients with PAH were more likely to show lower blood pressure, workload, and V · E / V · co 2 slope than did patients with CTEPH. 6MWT results, on the other hand, were similar for the 2 groups. Figure 1 shows peak HR and lowest Sp o 2 as assessed by CPET and 6MWT for patients with PAH and CTEPH. For patients with PAH, peak HR during CPET was significantly higher than during the 6MWT (132.1 ± 20.6 beats/ min vs 109.5 ± 17.1 beats/min; P < .0001), whereas lowest Sp o 2 during CPET and 6MWT was similar (86.5% ± 8.6% vs 86.6% ± 6.0%; P = .93). Similarly for patients with CTEPH, CPET peak HR was signifi cantly higher than 6MWT HR (131.4 ± 20.0 beats/min vs 106.8 ± 15.3 beats/ min; P < .0001), and lowest Sp o 2 as assessed by means of CPET and 6MWT proved to be similar (88.5% ± 4.1% vs 88.2% ± 3.9%; P = .75).
COMPARISON OF CPET AND 6MWT DATA FOR PATIENTS WITH PAH AND CTEPH
COMPARING ASSOCIATIONS OF EXERCISE TOLERANCE WITH RHC DATA FOR PATIENTS WITH PAH AND CTEPH
Associations of exercise tolerance with RHC data for PAH and CTEPH patients are shown in Figures 2 and 3 . For patients with PAH, signifi cant correlations were observed between peak V · o 2 and CI ( r = 0.59, P = .002) and between V · E / V · co 2 and CI ( r = − 0.46, P = .02). Moreover, patients with PAH had a trend for a signifi cant correlation between peak V · o 2 and PVR ( r = − 0.39, P = .05), but results were not statistically signifi cant between V · E / V · co 2 and PVR (r = 0.39, P = .06). For CTEPH patients, on the other hand, signifi cant correlation was observed only between V · E / V · co 2 and CI ( r = − 0.38, P = .02).
DISCUSSION
The fi ndings from this study demonstrate that peak HR during CPET was signifi cantly higher than HR during the 6MWT, whereas lowest Sp o 2 during CPET and 6MWT was similar for patients with PAH and CTEPH. A noteworthy difference in associations was observed between exercise tolerance and RHC data for patients with PAH and CTEPH despite similar baseline characteristics for the 2 disorders. Most investigations of patients with PAH and CTEPH have focused on cardiac function at rest. In addition, the therapeutic effects on exercise capacity for such patients have been commonly based on results of 6MWT. However, in a recent meta-analysis of 6MWT fi ndings in patients with PAH, improvement in 6MWT results was not benefi cial in terms of clinical outcomes. 13 The fi ndings in our study confi rm those previously reported that CPET is more effective than 6MWT for measuring maximum exercise tolerance for patients with PH. 14 , 15 On the other hand, Lammers et al Figure 1 . reported that 6MWT refl ects symptomatic maximum exercise test compared with CPET using cycle ergometry in children with PH with a 6MWD below 300 m. Although this study and the present one produced different fi ndings, our study used 57 elderly patients with PH with a mean 6MWD of 349 m. Peak V · o 2 and V · E / V · co 2 slopes correlated with CI and PVR for all patients with PH, whether PAH or CTEPH, [16] [17] [18] because an increase in PVR produces a decrease in blood fl ow to the left side of the heart, thus resulting in a lower CI. Our study found that hemodynamic parameters including CI and PVR were associated with parameters during CPET, including peak V · o 2 and V · E / V · co 2 slope for patients with PAH. Differences in correlations between exercise tolerance and hemodynamic parameters may refl ect differences in the pathophysiology of PAH and CTEPH. Zhai et al 19 reported that physiologic ventilatory dead space fraction measured at peak exercise by using arterial blood gas analysis and V · E / V · co 2 slopes were higher for patients with CTEPH than for those with PH. They suggested that common prognostic end points determined by CPET cannot be applied to all forms of PH. Furthermore, a previous study has shown that abnormal pulmonary vascular and right ventricular reserve during CPET was observed in patients with CTEPH with normalized resting mPAP after pulmonary endarterectomy compared with healthy controls. 20 This may support our fi ndings of the differences in hemodynamic parameters during CPET for PAH and CTEPH.
CLINICAL IMPLICATIONS
PAH is a main subgroup of PH, which includes disease processes that lead to increased right ventricular load, whereas CTEPH is another PH subgroup with symptoms and a clinical picture that are partly similar to those of PAH. Despite the differences in etiologies between PAH and CTEPH, both are primarily characterized by vascular remodeling that results in progressive right heart failure and death. [21] [22] [23] However, several treatment options have become available for patients with various forms of PH, especially PH-specifi c vasodilators for patients with PAH, and balloon pulmonary angioplasty or pulmonary endarterectomy for patients with CTEPH. Given the poor prognosis for both diseases, treatment compliance and followup are thus very important. As described earlier, the associations of exercise tolerance with hemodynamic parameters are different for patients with PAH and CTEPH because of differences in their pathophysiology. CPET may therefore constitute a better noninvasive management procedure for patients with PAH and CTEPH, so that evaluation of exercise tolerance during followup has become increasingly important in view of the etiology of PH. 
STUDY LIMITATION
This study involved a small number of patients in a single-center retrospective study, so that future studies of larger patient populations are necessary to validate our fi ndings. Furthermore, because only patients who could pedal a cycle ergometer were enrolled in this study, there is a possibility of some selection bias.
CONCLUSION
CPET is more useful than 6MWT as a maximum exercise test for patients with PAH and CTEPH. Peak V · o 2 and V · E / V · co 2 slopes correlated with CI for patients with PAH, and V · E / V · co 2 slopes only correlated with CI for patients with CTEPH. These differences might be the result of different pathophysiology between patients with PAH and CTEPH. Thus, PH etiology should be taken into consideration when assessing exercise tolerance, and CPET may, therefore, be useful in addition to hemodynamic assessment by means of RHC for periodic followup evaluations. 
